This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n4http://localhost/temp/predkladatel/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F09%3A10223890%21RIV12-MSM-15110___/
n18http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F09%3A10223890%21RIV12-MSM-15110___
rdf:type
skos:Concept n18:Vysledek
dcterms:description
Background: Targeted agents present with a new spectrum of side-effects, including toxicities that negatively impact the risk of atherosclerosis. The aim of the present study was to evaluate the effect of the combination of targeted therapy and chemotherapy on serum homocysteine and other laboratory parameters of cardiovascular risk in patients with metastatic colorectal carcinoma. Patients and Methods: Thirty-one patients with metastatic colorectal carcinoma treated with the combination of bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin were studied before and during the therapy. Results: Serum homocysteine decreased significantly throughout the course of treatment. Background: Targeted agents present with a new spectrum of side-effects, including toxicities that negatively impact the risk of atherosclerosis. The aim of the present study was to evaluate the effect of the combination of targeted therapy and chemotherapy on serum homocysteine and other laboratory parameters of cardiovascular risk in patients with metastatic colorectal carcinoma. Patients and Methods: Thirty-one patients with metastatic colorectal carcinoma treated with the combination of bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin were studied before and during the therapy. Results: Serum homocysteine decreased significantly throughout the course of treatment.
dcterms:title
Serum Homocysteine, Cholesterol, Retinol, alpha-Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin Serum Homocysteine, Cholesterol, Retinol, alpha-Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin
skos:prefLabel
Serum Homocysteine, Cholesterol, Retinol, alpha-Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin Serum Homocysteine, Cholesterol, Retinol, alpha-Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin
skos:notation
RIV/61989592:15110/09:10223890!RIV12-MSM-15110___
n3:aktivita
n16:S n16:P
n3:aktivity
P(NR9096), S
n3:cisloPeriodika
11
n3:dodaniDat
n6:2012
n3:domaciTvurceVysledku
n15:5290791
n3:druhVysledku
n13:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
340898
n3:idVysledku
RIV/61989592:15110/09:10223890
n3:jazykVysledku
n9:eng
n3:klicovaSlova
metastatic colorectal carcinoma; homocysteine; Bevacizumab
n3:klicoveSlovo
n10:metastatic%20colorectal%20carcinoma n10:homocysteine n10:Bevacizumab
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[E6A098D03376]
n3:nazevZdroje
ANTICANCER RESEARCH
n3:obor
n8:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
9
n3:projekt
n11:NR9096
n3:rokUplatneniVysledku
n6:2009
n3:svazekPeriodika
29
n3:tvurceVysledku
Kalábová, Hana Melichar, Bohuslav Krčmová, L. Malířová, E. Kašparová, M.
s:issn
0250-7005
s:numberOfPages
8
n4:organizacniJednotka
15110